Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
Octocog alfa
Bayer AG
B02BD02
octocog alfa
Antihemorrhagics
Hemophilia A
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency).This preparation does not contain von Willebrand factor and is therefore not indicated in von Willebrand's disease.
Revision: 31
Withdrawn
2000-08-04
23 B. PACKAGE LEAFLET Medicinal product no longer authorised 24 PACKAGE LEAFLET: INFORMATION FOR THE USER HELIXATE NEXGEN 250 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION HELIXATE NEXGEN 500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION HELIXATE NEXGEN 1000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION HELIXATE NEXGEN 2000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION HELIXATE NEXGEN 3000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION Recombinant coagulation factor VIII (octocog alfa) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or your pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Helixate NexGen is and what it is used for 2. What you need to know before you use Helixate NexGen 3. How to use Helixate NexGen 4. Possible side effects 5. How to store Helixate NexGen 6. Contents of the pack and other information 1. WHAT HELIXATE NEXGEN IS AND WHAT IT IS USED FOR Helixate NexGencontains the active substance human recombinant coagulation factor VIII (octocog alfa). Helixate NexGen is used for treatment and prophylaxis of bleeding adults, adolescents and children of all ages with haemophilia A (congenital factor VIII deficiency). This preparation does not contain von Willebrand factor and is therefore not to be used in von Willebrand's disease. The vial contains a dry white to slightly yellow powder or cake, as well as water for injections to be used to reconstitute the contents of the vial. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE HELIXATE NEXGEN DO NOT USE HELIXATE NEXGEN if you are allergic to octocog alfa or to any of the oth Przeczytaj cały dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT Helixate NexGen 250 IU powder and solvent for solution for injection Helixate NexGen 500 IU powder and solvent for solution for injection Helixate NexGen 1000 IU powder and solvent for solution for injection Helixate NexGen 2000 IU powder and solvent for solution for injection Helixate NexGen 3000 IU powder and solvent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains nominally 250/500/1000/2000/3000 IU human coagulation factor VIII (INN: octocog alfa). Human coagulation factor VIII is produced by recombinant DNA technology (rDNA) in baby hamster kidney cells containing the human factor VIII gene. One mL Helixate NexGen 250 IU contains approximately 100 IU (250 IU / 2.5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections. One mL Helixate NexGen 500 IU contains approximately 200 IU (500 IU / 2.5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections. One mL Helixate NexGen 1000 IU contains approximately 400 IU (1000 IU / 2.5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections. One mL Helixate NexGen 2000 IU contains approximately 400 IU (2000 IU / 5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections. One mL Helixate NexGen 3000 IU contains approximately 600 IU (3000 IU / 5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections. The potency (IU) is determined using the one-stage clotting assay against the FDA Mega standard which was calibrated against WHO standard in International Units (IU). The specific activity of Helixate NexGen is approximately 4000 IU/mg protein. For the full list of excipients, see section 6.1. 3. PHARMACEU Przeczytaj cały dokument